News Medical on MSN6d
High discontinuation rates of GLP-1 agonists found among patients with obesity
Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
GlobalData on MSN3d
Palatin concludes Phase II trial of combination therapy for obesity
Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
Morningstar10d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
Nature1mon
Peptide gut hormones influence weight loss after gastric bypass
Gut hormones that influence satiety, such as peptide YY (PYY ... the role of gut hormones in appetite change after Roux-en-Y gastric bypass. Le Roux et al. measured fasting and postprandial ...